COMMUNIQUÉS West-GlobeNewswire

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
DBV Technologies participera à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs
05/06/2026
Châtillon, France, le 5 juin (22 :30 CEST) 2026 DBV Technologies participera à la 47 ème conférence annuelle Global Healthcare organisée par Goldman Sachs DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq [...]
TerrAscend Schedules Special Meeting of Shareholders in Preparation for U.S. Stock Exchange Uplisting
05/06/2026
Special meeting will allow shareholders to vote on share consolidation to support potential uplisting to a U.S. stock exchange TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
05/06/2026
New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing 1 and up to 83% of caregivers noting [...]
Vivex Biologics Publishes New Medicare Real-World Evidence Study Showing VIA Disc® NP Significantly Reduces Opioid Use, Imaging, and Conservative Care Utilization in Patients with Lumbar Discogenic Pain
05/06/2026
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
05/06/2026
Nantes, le 5 juin 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress
05/06/2026
PRESS RELEASE First-in-class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients [...]
Victoire : un projet de loi vise à encadrer la vente des boissons énergisantes caféinées aux jeunes de moins de 16 ans
05/06/2026
MONTRÉAL, 05 juin 2026 (GLOBE NEWSWIRE) -- Cœur + AVC et le Collectif Vital applaudissent le dépôt du projet de loi 9, Loi visant à prévenir les effets nocifs de la boisson énergisante sur la santé des jeunes , ou [...]
EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
05/06/2026
SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill [...]
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
05/06/2026
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: [...]
Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $
05/06/2026
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $ Mont-Saint-Guibert, Belgique – 5 juin 2026, 17h25 CET / 11h25 ET - Nyxoah SA ( [...]
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
05/06/2026
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 [...]
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
05/06/2026
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers [...]
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
05/06/2026
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Substantial increases in daily “Good On” [...]

Pages